Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022

Details

• Journal Article:
  Morbidity and Mortality Weekly Report (MMWR)
• Personal Author:
  Klein, Nicola P. ; Stockwell, Melissa S. ; Demarco, Maria ; Gaglani, Manjusha ; Kharbanda, Anupam B. ; Irving, Stephanie A. ; Rao, Suchitra ; Grannis, Shaun J. ; Dascomb, Kristin ; Murthy, Kempapura ; Rowley, Elizabeth A. ; Dalton, Alexandra F. ; DeSilva, Malini B. ; Dixon, Brian E. ; Natarajan, Karthik ; Stenehjem, Edward ; Naleway, Allison L. ; Lewis, Ned ; Ong, Toan C. ; Patel, Palak ; Konatham, Deepika ; Embi, Peter J. ; Reese, Sarah E. ; Han, Jungmi ; Grisel, Nancy ; Goddard, Kristin ; Barron, Michelle A. ; Dickerson, Monica ; Liao, I-Chia ; Fadel, William F. ; Yang, Duck-Hye ; Arndorfer, Julie ; Fireman, Bruce ; Griggs, Eric P. ; Valvi, Nimish R. ; Hallowell, Carly ; Zerbo, Ousseny ; Reynolds, Sue ; Ferdinands, Jill ; Wondimu, Mehiret H. ; Williams, Jeremiah ; Bozio, Catherine H. ; Link-Gelles, Ruth ; Azziz-Baumgartner, Eduardo ; Schrag, Stephanie J. ; Thompson, Mark G. ; Verani, Jennifer R.
• Description:
  The efficacy of the BNT162b2 (Pfizer-BioNTech) vaccine against laboratory-confirmed COVID-19 exceeded 90% in clinical trials that included children and adolescents aged 5-11, 12-15, and 16-17 years (1-3). Limited real-world data on 2-dose mRNA vaccine effectiveness (VE) in persons aged 12-17 years (referred to as adolescents in this report) have also indicated high levels of protection against SARS-CoV-2 (the Virus that causes COVID-19) infection and COVID-19-associated hospitalization (4-6); however, data on VE against the SARS-CoV-2 B.1.1.529 (Omicron) Variants and duration of protection are limited. Pfizer-BioNTech VE data are not available for children aged 5-11 years. In partnership with CDC, the VISION Network* examined 39,217 emergency department (ED) and urgent care (UC) encounters and 1,699 hospitalizations| among persons aged 5-17 years with COVID-19-like illness across 10 states during April 9, 2021-January 29, 2022,| to estimate VE using a case-control test-negative design. Among children aged 5-11 years, VE against laboratory-confirmed COVID-19-associated ED and UC encounters 14-67 days after dose 2 (the longest interval after dose 2 in this age group) was 46%. Among adolescents aged 12-15 and 16-17 years, VE 14-149 days after dose 2 was 83% and 76%, respectively; VE ≥150 days after dose 2 was 38% and 46%, respectively. Among adolescents aged 16-17 years, VE increased to 86% ≥7 days after dose 3 (booster dose). VE against COVID-19-associated ED and UC encounters was substantially lower during the Omicron predominant period than the B.1.617.2 (Delta) predominant period among adolescents aged 12-17 years, with no significant protection ≥150 days after dose 2 during Omicron predominance. However, in adolescents aged 16-17 years, VE during the Omicron predominant period increased to 81% ≥7 days after a third booster dose. During the full study period, including pre-Delta, Delta, and Omicron predominant periods, VE against laboratory-confirmed COVID-19-associated hospitalization among children aged 5-11 years was 74% 14-67 days after dose 2, with wide CIs that included zero. Among adolescents aged 12-15 and 16-17 years, VE 14-149 days after dose 2 was 92% and 94%, respectively; VE ≥150 days after dose 2 was 73% and 88%, respectively. All eligible children and adolescents should remain up to date with recommended COVID-19 vaccinations, including a booster dose for those aged 12-17 years.
• Subjects:
  Adolescent Ambulatory Care BNT162 Vaccine Child Child, Preschool COVID-19 COVID-19 Vaccines Emergency Service, Hospital Female Hospitalization Humans Immunization, Secondary Male SARS-CoV-2 Vaccine Efficacy

  More +
• Source:
  MMWR Morbidity Mortal Weekly Rep. 71(9):352-358
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• DOI:
  http://dx.doi.org/10.15585/mmwr.mm7109e3
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Pubmed ID:
  35239634
• Pubmed Central ID:
  PMC8893336
• Document Type:
  Journal Article
• Place as Subject:
  United States
• Pages in Document:
  7 pdf pages
• Volume:
  71
• Issue:
  9
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:90092a91e5f22b70c128b3197c983b9955b98401259c7045013cb84e26c26547c530973a3a2e78ae0b6b3aed14703e018b2ea812f28a4fcd9eb4358ee8c385c5
• Download URL:
  https://stacks.cdc.gov/view/cdc/115831/cdc_115831_DS1.pdf
• File Type:
  [PDF - 162.02 KB ]